Eli Lilly has released a new vial version of its blockbuster weight loss drug Zepbound for around half the price of its original injectable pen, as its battle with Novo Nordisk to boost production for the wildly popular medicine heats up.
The Indianapolis-based drugmaker said it had launched single-dose vials of Zepbound at two different concentrations, priced at $399 and $549 for a four-week supply, about half the wholesale list price of the original form.
Zepbound is typically sold in an injector pen, which packages the drug together with the needle used to administer it. Patients using its new vial will need to buy their own syringes to use it, cutting down the time taken to produce the dose.
您已阅读24%（705字），剩余76%（2276字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。